2MD, a new anabolic agent for osteoporosis treatment

Author： Plum Lori   Fitzpatrick Lorraine   Ma Xiaohong   Binkley Neil   Zella Julia   Clagett-Dame Margaret   DeLuca Hector  

Publisher： Springer Publishing Company

ISSN： 0937-941X

Source： Osteoporosis International, Vol.17, Iss.5, 2006-05, pp. : 704-715

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

AN ANABOLIC AGENT IN THE TREATMENT OF THE CHRONICALLY ILL

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 10, Iss. 9, 1962-09 ,pp. : 749-754

John Wiley & Sons Inc

Access to resources Recommend Favorite

A NEW ANABOLIC AGENT (STANOZOLOL): CLINICAL EVALUATION IN THE AGED

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 11, Iss. 5, 1963-05 ,pp. : 449-456

John Wiley & Sons Inc

Access to resources Recommend Favorite

Regulatory pathways revealing new approaches to the development of anabolic drugs for osteoporosis

By Martin T.   Sims N.   Ng K.  

Osteoporosis International, Vol. 19, Iss. 8, 2008-08 ,pp. : 1125-1138

Springer Publishing Company

Access to resources Recommend Favorite

Anabolic therapy for osteoporosis

By Bilezikian John P  

Women's Health, Vol. 3, Iss. 2, 2007-03 ,pp. : 243-253

Future Medicine

Access to resources Recommend Favorite

Emerging Anabolic Treatments in Osteoporosis

By  

Current Drug Safety, Vol. 6, Iss. 2, 2011-04 ,pp. : 62-74

Bentham Science Publishers

Access to resources Recommend Favorite